Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q-linea AB ( (SE:QLINEA) ) has shared an announcement.
Q-linea AB announced that the Italian Supreme Administrative Court has overturned a previous ruling in their favor regarding the ESTAR tender for rapid AST. Although the tender, valued at EUR 1.7 million over five years, is not yet formally awarded, Q-linea assesses its chances of winning as low. Despite this setback, the company maintains a positive outlook on the Italian market.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea is a Swedish company headquartered in Uppsala, specializing in rapid antimicrobial susceptibility testing (AST) systems. Their primary product, ASTar®, is designed to accelerate and simplify workflows in treating bloodstream infections and sepsis, helping hospitals reduce the time to optimal antimicrobial therapies. The company operates with regional offices in Italy and the USA and has global partnerships.
Average Trading Volume: 19,102
Technical Sentiment Signal: Sell
Current Market Cap: SEK311.4M
For detailed information about QLINEA stock, go to TipRanks’ Stock Analysis page.